# Viswa Colluru

> Viswa Colluru is the founder and CEO of Enveda, a Boulder-based clinical-stage biotechnology company that combines metabolomics, machine learning, automation and teams in Colorado and Hyderabad to search nature’s chemistry for new small-molecule medicines. Trained in biotechnology and cellular and molecular biology, he moved from academic immuno-oncology to product and portfolio roles at Recursion before starting Enveda in 2019 with $55,000 of personal savings.

- **Role:** Founder and CEO at Enveda
- **Organizations:** Enveda, Recursion Pharmaceuticals, Wisconsin Alumni Research Foundation, University of Wisconsin-Madison
- **Education:** Bachelor of Technology in Biotechnology, GITAM College of Engineering, Andhra University, PhD in Cellular and Molecular Biology, University of Wisconsin-Madison, HBX CORe Credential of Readiness, Harvard Business School Online
- **Known for:** Founded Enveda in 2019 and scaled it from $55,000 of personal savings into a clinical-stage biotechnology company., Built a company platform combining metabolomics, machine learning and automation to analyze complex natural chemistry., Led Enveda through a $150 million Series D in 2025 and more than $500 million in disclosed total capital.

## Career timeline

- **2013-2016** — Worked as a technology transfer ambassador at the Wisconsin Alumni Research Foundation while completing doctoral research.
- **2016** — Joined Recursion as its first Innovation Scientist.
- **2017-2019** — Moved through product, project leadership and portfolio or early-commercial responsibilities at Recursion.
- **2019** — Left Recursion and founded Enveda with $55,000 of personal savings.
- **2023** — Was named a UBS Global Visionary.
- **2024** — Enveda announced that its first platform-discovered candidate had advanced to clinical trials.
- **2025** — Enveda closed a $150 million Series D, reached unicorn status and reported total funding of $517 million.
- **2026** — Enveda reported multiple clinical readouts and continued advancing a multi-asset pipeline.

## Achievements

- Founded Enveda in 2019 and scaled it from $55,000 of personal savings into a clinical-stage biotechnology company.
- Built a company platform combining metabolomics, machine learning and automation to analyze complex natural chemistry.
- Led Enveda through a $150 million Series D in 2025 and more than $500 million in disclosed total capital.
- Was named a UBS Global Visionary in 2023.
- Serves in the World Economic Forum's Unicorn Innovator Community.
- Was the youngest PhD graduate from the University of Wisconsin-Madison CMB class that entered in 2011.
- Developed candidate immunotherapies and published research on DNA vaccines during doctoral training.

## Latest updates

- **2026-08** — Enveda reported positive Phase 1 results for ENV-308, its third clinical-stage asset.
- **2026-07** — Enveda presented positive Phase 1b results for ENV-294 and said additional details would follow at EADV.
- **2026-04** — Colluru discussed Enveda’s natural-product discovery model in long-form interviews with The Generalist and Scottish Mortgage.
- **2026-03** — Enveda reported positive Phase 1b results for ENV-294.
- **2025-09** — Enveda announced a $150 million Series D, its first patient in an ENV-294 Phase 1b study and Mikael Dolsten’s appointment to the board.

## Links

- Website: https://enveda.com
- LinkedIn: https://www.linkedin.com/in/viswacolluru
- Twitter/X: https://x.com/viswacolluru
- YouTube: https://www.youtube.com/watch?v=BCpsdLece7E

---

Profile page: https://yespress.io/viswa-colluru
Published by YesPress — https://yespress.io
Last updated: 2026-08-27